Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Rescue Combination for MRSA Pneumonia With Pneumothorax

Published: Wed, 27 Sep 2017 12:00:00 EDT
The authors describe a combination therapy for the successful treatment of a case of severe community-acquired MRSA pneumonia complicated by pneumothorax.
BMC Pulmonary Medicine

Aspirin Challenge and Desensitization: How, When and Why

Published: Fri, 22 Sep 2017 12:00:00 EDT
Learn which patients may safely undergo low-dose aspirin challenge/desensitization procedures.
Current Opinion in Allergy and Clinical Immunology

A 19-Year-Old Woman With Abdominal Pain and Diarrhea

Published: Fri, 22 Sep 2017 12:00:00 EDT
A 19-year-old woman presents due to fevers, nausea, severe abdominal pain, and watery diarrhea. The symptoms have been on-and-off over the past few months. What treatment is indicated?

Mutational Profiles of Primary Myelofibrosis and Other MPNs

Published: Fri, 22 Sep 2017 12:00:00 EDT
This study analyzed the mutational profiles and cytogenetic abnormalities of three common chronic myeloproliferative neoplasms, with the aim of facilitating diagnosis between them.
American Journal of Clinical Pathology
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


EuroBiotech Report—Bavarian Nordic, Nabriva, Immunocore, Glythera-Iontas and Sanofi

Published: Thu, 21 Sep 2017 13:39:03 +0000
In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more. 

Celgene-backed FLX picks CCR4 antagonist for clinical trials

Published: Thu, 21 Sep 2017 13:10:06 +0000
FLX Bio has picked a clinical candidate from its CCR4 antagonist program. The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.

Janssen deal gives new kid in town Provention two immune candidates

Published: Thu, 21 Sep 2017 12:05:14 +0000
Right on the heels of a $28 million seed financing, Provention Bio has snapped up two inflammatory bowel disease candidates from Janssen that should make it a double clinical-stage biotech next year.

First biotech emerges from Garabedian’s accelerator armed with $10M, plans to tackle autoimmune diseases

Published: Thu, 21 Sep 2017 10:35:00 +0000
Chris Garabedian’s accelerator has spawned its first biotech. The startup, Landos Biopharma, has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million from Perceptive Advisors to take a LANCL2-targeted treatment for inflammatory bowel disease into the clinic.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy